Aniling
Accelerating Epigenomics for Precision Medicine against cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 10 % | - | 10 % | - | 4639 % | 40 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (211 %) | (296 %) | (435 %) | (451 %) | 31 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 435 % | (140 %) | (246 %) | (312 %) | 13 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Aniling is a biotechnology company specializing in diagnostics through its proprietary GEUS technology, which unifies genetic and epigenetic sequencing. The company primarily serves laboratories and hospitals by providing comprehensive diagnostic tests for cancer, such as its flagship product, the GEUS CLL panel for Chronic Lymphocytic Leukemia. Operating in the genomics and precision medicine market, Aniling's business model revolves around offering diagnostic services and products that enable accurate staging and treatment decisions in oncology. The company generates revenue by selling these diagnostic tests and services to healthcare institutions. Aniling aims to bring advancements in genomics to everyday healthcare and disease prevention, accelerating the adoption of precision medicine. The company is a spin-off from the Institute of Predictive and Personalized Medicine of Cancer (IMPPC) and is currently integrated into the Germans Trias i Pujol Biomedical Research Institute (IGTP). Aniling has also successfully renewed its ISO 13485:2016 certification, underscoring its commitment to quality and reliability in medical device manufacturing.
Keywords: Genomics, Epigenomics, Oncology, Diagnostics, GEUS Technology, Precision Medicine, Chronic Lymphocytic Leukemia, ISO 13485, Biotechnology, Healthcare.